How IPTLD Works

A chemotherapy drug circulating in the bloodstream has done nothing useful yet. To have any effect it must cross the membrane of a cancer cell and, for a number of drug classes, be chemically converted once inside. These are two separate obstacles, and either one can limit how well treatment works.

The first gate is transport. Many chemotherapy agents are water-soluble molecules that cannot simply diffuse through the fatty cell membrane. They rely on dedicated transport proteins embedded in that membrane to carry them across. Nucleoside-analogue chemotherapies, for example, depend on transporter families known as equilibrative and concentrative nucleoside transporters. The amount of transporter a tumour expresses is not a minor detail - for some agents, transporter levels measured in tumour tissue are used to predict how well a patient is likely to respond. Cells with little transporter are substantially resistant, regardless of how much drug is given.

The second gate is activation. Several important chemotherapy drugs are given in an inactive form - a prodrug. Once inside the cell, enzymes must attach phosphate groups before the drug becomes biologically active. That conversion step is rate-limited by the enzyme’s capacity, and the enzyme is itself regulated by the cell’s internal nucleotide balance.

These gates operate in sequence. Increasing how much drug crosses the membrane only translates into effect if the cell can also activate it - which is one reason simply escalating dose has diminishing returns, while improving uptake efficiency can matter a great deal.

Here the biology becomes genuinely elegant. When a prodrug is activated inside the cell, the phosphate groups added during activation carry a strong negative electrical charge. Charged molecules cannot pass back out through the fatty cell membrane. The drug is, in effect, locked in.

The consequence is that the treatment session and the drug’s period of activity are not the same thing. Measured intracellular elimination of the activated form is markedly slower than clearance of the parent drug from the bloodstream. Published clinical pharmacokinetic studies report terminal intracellular half-lives of roughly five to seven hours, extending in some patients to around twelve - so while the infusion may be over within the hour, activated drug remains inside the cell well into the same day.

This also explains why uptake efficiency matters disproportionately. Because the active form is retained rather than continuously washed out, a modest increase in how much drug enters during the exposure window produces a much larger increase in the cell’s total drug exposure over the following day. A 2020 review of intracellular pharmacokinetics in Clinical Pharmacokinetics makes the underlying point directly: “the intracellular accumulation of nucleotides appears critical to the cytotoxicity of pyrimidine analogues”, and “understanding the plasma pharmacokinetics is therefore not enough - it is important to investigate the extent to which these agents enter the cell, are activated intracellularly and actually reach their target in the activated form.”

Our treatment week is built around two IPTLD sessions and a mega-dose Vitamin C session - three metabolically active treatments, spaced across the week rather than concentrated into a single intensive dose. That structure is deliberate.

Different cells are reachable at different times. Because tumour cells cycle in and out of vulnerable phases independently of one another, any single treatment can only reach the fraction that happens to be susceptible at that moment. Repeated, spaced exposure addresses a different portion of the tumour population each time.

Repetition produces adaptations a single exposure cannot. Some cellular responses to metabolic signalling are not instantaneous relocations of existing proteins but changes in how much transporter protein the cell manufactures - a process that unfolds over hours. A single brief exposure is too short for this. A pattern sustained three times weekly over a course of treatment is not. Repeated metabolic stimulation has been shown to progressively increase transport capacity in other tissue contexts.

The drug's activity outlasts the session. With active drug persisting inside cells for the better part of a day, sessions spaced across the week produce overlapping windows of activity rather than isolated events.

The protocol is therefore designed as a sustained rhythm rather than a single intervention - built around how the medicine behaves inside cells, and around how tumours actually cycle.

At the concentrations achievable only by intravenous infusion, Vitamin C behaves quite differently from the vitamin taken orally. At these levels it acts as a pro-oxidant within tissue, generating hydrogen peroxide in the extracellular environment.

Normal cells are generally well equipped to neutralise hydrogen peroxide, carrying robust levels of the enzymes required. Many tumour cells carry markedly lower levels of those same enzymes, which is the basis of the selectivity proposed for this approach.

Vitamin C also shares a transport route with glucose - it enters cells through the same glucose transporters - which links it directly to the metabolic behaviour that makes tumours glucose-avid in the first place.

This session is placed between the two IPTLD sessions, contributing a third metabolically active treatment to the week.

We would rather you checked than took our word for it. The papers below are the published sources behind the mechanisms described on this page. Where a study is open access we have linked the full text, not just the abstract - so you can read the methods, the results and the authors’ own limitations for yourself.